학술논문

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
Document Type
Article
Author
Petrylak, Daniel Pde Wit, RonaldChi, Kim NDrakaki, AlexandraSternberg, Cora NNishiyama, HiroyukiCastellano, DanielHussain, SyedFléchon, AudeBamias, AristotelisYu, Evan Yvan der Heijden, Michiel SMatsubara, NobuakiAlekseev, BorisNecchi, AndreaGéczi, LajosOu, Yen-ChuanCoskun, Hasan SenolSu, Wen-PinHegemann, MiriamPercent, Ivor JLee, Jae-LyunTucci, MarcelloSemenov, AndreyLaestadius, FredrikPeer, AvivitTortora, GiampaoloSafina, Sufiadel Muro, Xavier GarciaRodriguez-Vida, AlejoCicin, IrfanHarputluoglu, HakanWidau, Ryan CLiepa, Astra MWalgren, Richard AHamid, OdayZimmermann, Annamaria HBell-McGuinn, Katherine MPowles, ThomasWong, Suet-Lai ShirleyTan, Thean HsiangHovey, Elizabeth JaneClay, Timothy DudleyNg, Siobhan Su WanRutten, AnnemieMachiels, Jean-PascalDumez, HerlindeCheng, Susanna Yee-ShanChi, Kim NguyenFerrario, CristianoSengeloev, LisaJensen, Niels ViggoThibault, ConstanceLaguerre, BrigitteLaestadius, FredrikJoly, FlorenceFlechon, AudeCuline, StéphaneBecht, CatherineNiegisch, GünterStöckle, MichaelGrimm, Marc-OliverGakis, GeorgiosSchultze-Seemann, WolfgangKalofonos, HaralambosMavroudis, DimitriosPapandreou, ChristosKaravasilis, VasilisBamias, AristotelisRévész, JanosGeczi, LajosRosenbaum, EliLeibowitz-Amit, RayaKejzman, DanielPeer, AvivitSarid, DavidScagliotti, Giorgio VittorioSternberg, Cora NTortora, GiampaoloBracarda, SergioNecchi, AndreaMassari, FrancescoOsawa, TakahiroMiyajima, NaotoShinohara, NobuoFukuta, FumimasaOhyama, ChikaraObara, WataruYamashita, ShinichiTomita, YoshihikoKawai, KojiFukasawa, SatoshiMatsubara, NobuakiOyama, MasafumiYonese, JunjiNagata, MasayoshiUemura, MotohideNishimura, KazuoKawakita, MutsushiTsunemori, HiroyukiHashine, KatsuyoshiInokuchi, JunichiYokomizo, AkiraNagamori, SatoshiLee, Jae-LyunLee, Hyo JinPark, Se HoonRha, Sun YoungKim, Yu JungLee, Yun-GyooCortés, Leticia VazquezFlores, Claudia Lorena UrzuaBlaisse, Reinoud J Bvan der Heijden, Michiel Sde Wit, RonaldErdkamp, Fransiscus L GAarts, Maureen J BWojcik-Tomaszewska, JoannaTomczak, PiotrSikora-Kupis, BozenaSchenker, MichaelHerzal, Alina AmaliaUdrea, Anghel AdrianKarlov, PetrSafina, Sufia ZAlekseev, BorisSemenov, AndreyFomkin, RomanPulido, Enrique GrandeDel Muro, F Xavier GarcíaMignorance, Juan Ignacio DelgadoGauna, Daniel CastellanoRodríguez-Vida, AlejoSu, Yu-LiOu, Yen-ChuanLin, Chien-LiangSu, Wen-PinLin, Chia-ChiYeh, Su-PengÇiçin, IrfanHarputluoglu, HakanErman, MustafaCoskun, Hasan SenolUrun, YukselGolovko, YuriiBondarenko, IgorSinielnikov, IvanPowles, ThomasCrabb, SimonSyndikus, IsabelHuddart, RobertSundar, SanthanamChowdhury, SimonSarwar, NaveedDrakaki, AlexandraFlaig, ThomasPan, Chong XianPetrylak, DanielSchwarz, JamesPercent, IvorCultrera, JenniferHainsworth, JohnHerms, BenjaminLawler, WilliamLowe, ThomasTagawa, ScottAragon-Ching, JeannyVaishampayan, Ulka
Source
The Lancet; November 2017, Vol. 390 Issue: 10109 p2266-2277, 12p
Subject
Language
ISSN
01406736; 1474547X
Abstract
Few treatments with a distinct mechanism of action are available for patients with platinum-refractory advanced or metastatic urothelial carcinoma. We assessed the efficacy and safety of treatment with docetaxel plus either ramucirumab—a human IgG1 VEGFR-2 antagonist—or placebo in this patient population.